Preparation and Evaluation of Inclusion Complex of Lansoprazole with 2-HP-β-Cyclodextrin and Meglumine
![]() |
Lee, Jung-Woo
(College of Pharmacy, Chungnam National University)
Kim, Jung-Su (College of Pharmacy, Chungnam National University) Chang, Hye-Jin (College of Pharmacy, Chungnam National University) Lee, Gye-Won (Dept. of Pharmaceutical Engineering, Konyang University) Jee, Ung-Kil (College of Pharmacy, Chungnam National University) |
1 | T. Loftsson and M.E. Brewster, Pharmaceutical applications of cyclodextrins. 1. drug solubilization and stabilization, J. Pharm. Sci., 85, 1017 (1996) DOI ScienceOn |
2 | R.A. Rajewsky and V.J. Stella, Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci., 85, 1142 (1996) DOI ScienceOn |
3 |
K. Diezel, K.S. Estes, M.E. Brewster, N.S. Bodor and N. Derendorf, The use of 2-hydroxypropyl- |
4 | T. Tabata, T. Makino, T. Kashihara, S. Hirai, N. Kitarnori and H. Toguchi, Stabilization of a new antiulcer drug(lansoprazole) in the solid dosage fonns, Drug Dev. Ind. Pharm., 18, 1437-1447 (1992) DOI |
5 | L.B. Baradell, D. Faulds and D. McTavish, Lansoprazole: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders, Drugs, 44, 225-250 (1992) DOI ScienceOn |
6 | A.E. Zimmennann and B.G. Katona, Lansoprazole: A comprehensive review, Pharmacotherapy, 17, 308-326 (1997) |
7 | A. Kristl and F. Vrecer, Prefonnulation investigation of the novel proton pump inhibitor lansoprazole, Drugs Dev. Ind. Pharm., 26, 781-783 (2000) DOI ScienceOn |
8 | A.B. Robert, Lansoprazole and omeprazo1e in the treatment of acid peptic disorders, Am. J. Health-Syst. Pharm., 53, 1401-1415 (1996) |
9 | T. Irie and K Vekama, Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation. J. Pharrri. Sci., 82, 147 (1997) |
10 |
A. Yoshida, H. Arima, K. Uekama and J. Pitha, Pharma-ceutical evaluation of hydroxyalkyl ethers of |
11 | M.E. Brewster, K.S. Estes and N. Bodor, Development of a non-surfactant fonnulation for alfaxalone through the use of chemically-modified cyclodextrins. J. Parenteral Sci. Technol., 43, 262 (1989) |
12 | M. Pederson, M. Edelsten, V.F. Nielson, A. Scarpellini, S. Skytte and C. Slot, Formation and antimycotic effect of cyclodextrin inclusion complexes of econazole and miconazole. Int. J. Pharm., 90, 247 (1993) DOI ScienceOn |
13 |
M.E. Brewster, K.S. Estes and N. Bodor, An intravenous toxicity study of hydroxypropyl- |
14 |
P. Putteman, W. Caers, J. Mesens and J. Peeters, Recent topics with regard to the use of Encapsin |
15 | G. Piel, B. Evrard, M. Fillet, G. Liabres and L. Delattre, Development of a non-surfactant parenteral fonnulation. of mitoconazole by the use of cyclodextrins. Int. J. Pharm., 169, 15 (1998) DOI ScienceOn |
16 |
W. Locher, D. Hoenack, A Richter, H. Schulz, M. Schuerer, R. Duesing and M.E. Brewster: New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl- |
17 | Gye Ju Rhee, Sung Wook Kim, Ki Chan Do, Chong Bum Park and Sung Joo Hwang, Complexation of omeprazole with meglumine and its stability, J. Kor. Pharm. Sci., 27(4), 253-263 (1997) |
18 | T. Higuchi and J.L. Lach, Investigation of some complexes fonned in solution by caffeine., J. Am. Pharm. Asso., 43(6), 349-354 (1954) DOI |
19 |
M. Tsuruoka, T. Hashimoto, H. Seo, S. Ichimasa, O. Veno, T. Fujinaga, M. Otagiri and K Vekama, Enhanced bioavailability of phenytoin by |
20 | A. Martin, K. Swarbrick and A Cammarata, Physical Pharmacy, 3rd ed., p. 325 (1983) |
21 |
M. Kurozumi, N. Nambu and T. Nagai, Inclusion compounds of non-steroidal anti-inflammatory and other slightly water soluble drugs with |
22 | T. Higuchi andKA Counors, Phase-solubility techniques. Acv. Anal. Chem. Instrum., 4, 117-212 (1965) |
23 | K. Uekama, T. Fujinaga, F. Hirayama, M. Otagiri and M. Yamasaki, Inclusion complexations of steroid honnone with cyclodextrins in water and solid-state. Int. J. Pharm., 10, 1-15 (1982) DOI ScienceOn |
![]() |